Retatrutide
Symbol Rt · MW 4731 Da
Triple-agonist peptide showing record weight-loss results in trials.
- Discovered
- 2022
- Half-life
- 6 days
- Approval
- Investigational
Reported effects
- Major weight loss
- Improved metabolism
- Lipid effects
Overview
Retatrutide is an investigational weight loss peptide known as a triple agonist because it targets GLP-1, GIP, and glucagon receptors. These three metabolic hormone pathways are involved in appetite regulation, insulin response, blood sugar control, and energy balance. Retatrutide is being studied for obesity, weight management, and metabolic health because it may combine appetite suppression with broader effects on energy expenditure and glucose metabolism. Unlike single-pathway GLP-1 peptides, Retatrutide is designed to influence multiple systems at the same time. It is considered one of the more advanced next-generation metabolic peptides, though it remains investigational and should not be treated as a standard approved weight loss medication.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- Investigational research range: 1–12 mg
- Typical Frequency
- Once weekly
Research sources
Source links included from peer-reviewed literature and trusted medical journal records for this peptide.
Interested in Retatrutide?
Enter your email and we'll send you a curated list of vendors we trust for sourcing this peptide.
No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions.